OncLive TV

Fernando C. Maluf, MD, PhD discusses the efficacy of platinum-based chemotherapy plus pembrolizumab in advanced penile squamous cell carcinoma.

Monzr M. Al Malki, MD, discusses outcomes with mismatched unrelated donor transplantation using post-transplant cyclophosphamide–based GVHD prophylaxis.

Antonio Martin Jimenez Jimenez, MD, discusses conditioning therapy, PBSC from HLA-MMUD, and PTCy for GVHD prophylaxis in hematological malignancies.

Michael Serzan, MD, discusses the use of botensilimab/balstilimab in the treatment of patients with advanced renal cell carcinoma.

Roger Li, MD, discusses patient outcomes from the KEYNOTE-057 trial in BCG–unresponsive, high-risk non–muscle-invasive bladder cancer.

Michael Deininger, MD, PhD, discusses 4-year outcomes with ponatinib in patients with chronic myeloid leukemia harboring a T315I mutation.

Shubham Pant, MD, MBBS, discusses the utility of zanidatamab in patients with previously treated HER2+ biliary tract cancer.

Kedar Kirtane, MD, discusses a phase 1b study of TBio-4101 plus pembrolizumab in patients with PD-1 inhibitor–resistant, advanced HNSCC.

Allison Winter, MD, discusses data from a retrospective analysis evaluating real-world outcomes with liso-cel in patients with Richter transformation.

Malcolm Mattes, MD, discusses the CTEP 10492 trial of ipatasertib plus chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.

Paolo Tarantino, MD, discusses updated data from the phase 3 DESTINY-Breast03 trial of trastuzumab deruxtecan in HER2-positive breast cancer.

Aditya Bardia, MD, MPH, FASCO, discusses standard first-, second-, and third-line HER2-positive metastatic breast cancer management approaches.

Giuseppe Curigliano, MD, PhD, discusses findings from the phase 3 DESTINY-Breast06 trial of T-DXd in HER2-low or HER2-ultralow metastatic breast cancer.

Mina Lobbous, MD, MPH, on tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases from HER2-positive breast cancer.

Noa Biran, MD, discusses the investigation of belantamab mafodotin plus bortezomib and dexamethasone in multiple myeloma.

Andrew Hantel, MD, discusses the influence of race/ethnicity and socioeconomic status on the timeliness of first-line treatment in acute myeloid leukemia.

Peter Forsyth, MD, discusses the importance of evaluating leptomeningeal disease caused by TNBC and HER2+ breast cancer.

Jakub Svoboda, MD, discusses the investigation of huCART19-IL18 in patients with relapsed/refractory lymphomas that have progressed.

Joaquim Bellmunt, MD, PhD discusses findings from a post-hoc analysis for avelumab maintenance in advanced urothelial carcinoma with low tumor burden.

María-Victoria Mateos, MD, PhD, discusses findings for belantamab mafodotin plus bortezomib and dexamethasone.

John L. Marshall, MD, discuss updates in colorectal cancer management at the 2024 ASCO Annual Meeting.

Petros Grivas, MD, PhD, and Chandler H. Park, MD, FACP, discuss key updates in genitourinary cancer on OncLive News Network: On Location.

Noopur S. Raje, MD, and Yan Leyfman, MD, discuss the phase 3 DREAMM-7 and DREAMM-8 trials on OncLive News Network: On Location.

Atish D. Choudhury, MD, PhD, on a phase 2 trial evaluating ADT interruption in metastatic hormone-sensitive prostate cancer after AR inhibitor response.

Benjamin Levy, MD, and Yan Leyfman, MD, discuss the clinical application of antibody-drug conjugates in non–small cell lung cancer.

Paolo Tarantino, MD, and Yan Leyfman, MD, discuss ongoing investigations into the treatment of HR+ breast cancer presented at the 2024 ASCO Annual Meeting.

Sujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.

Suzanne Trudel, MSc, MD, discusses key results and subgroup analyses from the phase 3 DREAMM-7 trial of BVd in relapsed/refractory multiple myeloma.

Consuelo Bertossi, MD, discusses the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia.

Michael R. Grunwald, MD, FACP, discusses disease progression in patients with low-risk myelofibrosis enrolled in the prospective MOST study.